NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Waypoint Bio

Waypoint Bio

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.waypointbio.com/

Last Round

Series A

May 27, 2026

Total Funding Raised

$34.5M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Waypoint Bio is a biotechnology company that develops next-generation cell therapies for solid tumors using a proprietary spatial pooled screening platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoveryfunctional genomicsai drug discoverytarget identificationhigh-throughput screeningin silico drug discoveryspatial genomicspredictive modelingbiotech platformtarget validationcomputational biologydrug developmentgenotype-phenotype mappingai-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Waypoint Bio Comps

Public and private peers based on sector, stage, and business model.

Waypoint Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Waypoint Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 27, 2026
SeedJun 28, 2024

Key People

Founding team and executive leadership

Xinchen Wang

Co-founder And CEO

Founding Team

Patrick Kaifosh

Chief Technology Officer

Executive Team

Waypoint Bio Investors

Notable investors and investment history

Waypoint Bio investors
InvestorRounds
Time BioVenturesSeries A
Mitsui Global InvestmentSeries A
Lux CapitalSeries A
Venture HighwaySeries A
Amplify PartnersSeries A
Fifty YearsSeed
Recode VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2026

    $20M round led by Amplify Partners.

  • Oct 21, 2025

    Patrick Kaifosh, formerly of Meta, appointed CTO.

Waypoint Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Waypoint Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Waypoint Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range20
Year Founded2021
Last FundingMay 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.